← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Schneeberger Daniel
10% Owner
Identity: SEC owner CIK matched through an unambiguous cached owner-name crosswalk · Reporting-owner CIK: 0001861120
Purchase history
- Companies traded
- 5
- Purchases · 12M
- 15
- Purchases · 24M
- 16
- Average purchase
- $1.3M
- Median purchase
- $716.4K
- Gross purchase value
- $21.0M
Companies: InMed Pharmaceuticals Inc. | Keros Therapeutics, Inc. | NextCure, Inc. | Rallybio Corp | TENAX THERAPEUTICS, INC.
16 SEC accession(s) · 16 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-10-15 | InMed Pharmaceuticals Inc. | INM | 10% Owner | $12.7K | Open filing |
| 2026-10-08 | InMed Pharmaceuticals Inc. | INM | 10% Owner | $14.5K | Open filing |
| 2026-10-05 | InMed Pharmaceuticals Inc. | INM | 10% Owner | $57.1K | Open filing |
| 2026-09-16 | InMed Pharmaceuticals Inc. | INM | 10% Owner | $118.1K | Open filing |
| 2026-09-08 | TENAX THERAPEUTICS, INC. | TENX | 10% Owner | $1.6M | Open filing |
| 2026-09-02 | TENAX THERAPEUTICS, INC. | TENX | 10% Owner | $1.4M | Open filing |
| 2026-08-24 | TENAX THERAPEUTICS, INC. | TENX | 10% Owner | $1.8M | Open filing |
| 2026-08-03 | NextCure, Inc. | NXTC | 10% Owner | $1.5M | Open filing |
| 2026-07-29 | NextCure, Inc. | NXTC | 10% Owner | $87.7K | Open filing |
| 2026-07-17 | InMed Pharmaceuticals Inc. | INM | 10% Owner | $1.6K | Open filing |
| 2026-05-21 | InMed Pharmaceuticals Inc. | INM | 10% Owner | $721.7K | Open filing |
| 2026-05-20 | Rallybio Corp | RLYB | 10% Owner | $226.6K | Open filing |
| 2026-05-15 | Rallybio Corp | RLYB | 10% Owner | $1.1M | Open filing |
| 2026-05-13 | Rallybio Corp | RLYB | 10% Owner | $711.1K | Open filing |
| 2026-05-06 | Rallybio Corp | RLYB | 10% Owner | $2.2M | Open filing |
| 2025-04-11 | Keros Therapeutics, Inc. | KROS | 10% Owner | $9.5M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 3Small Sample | 20.0% (3/15) | 33.3% (1/3) | -1.0% | -0.4% | -6.5% |
| 20D | 3Small Sample | 23.1% (3/13) | 66.7% (2/3) | +3.3% | +1.0% | -4.5% |
| 60D | 0No Data | 0.0% (0/7) | — | — | — | — |
| 120D | 0No Data | 0.0% (0/1) | — | — | — | — |
Research patterns
- First purchase in 12M
- 4/15
- Large purchase ≥ $100k
- 11/16
- Cluster buying · 15D
- 16/16
- Buying the dip
- 3/3
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.